uniQure N.V. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,907.20
6,214.40
10,451.60
25,098.00
13,107.00
11,284
Cost of Goods Sold (COGS) incl. D&A
1,772.40
-
5,063.30
-
-
-
Gross Income
2,134.80
-
5,388.20
-
-
-
SG&A Expense
32,227.90
57,779.90
68,881.70
92,420.00
91,064.00
87,814
EBIT
30,093.10
53,607.00
63,493.50
71,946.00
84,900.00
82,832
Unusual Expense
4,576.30
115.40
12,419.90
785.00
992.00
5,192
Non Operating Income/Expense
175.30
8,728.00
1,609.00
1,034.00
8,791.00
4,382
Interest Expense
1,189.50
4,589.50
2,342.00
2,172.00
2,475.00
2,160
Pretax Income
35,606.70
49,131.50
79,743.60
72,229.00
79,459.00
83,073
Income Tax
-
-
477.90
1,145.00
199.00
231
Consolidated Net Income
35,606.70
49,131.50
79,265.70
73,374.00
79,260.00
83,304
Net Income
35,606.70
49,131.50
79,265.70
73,374.00
79,260.00
83,304
Net Income After Extraordinaries
35,606.70
49,131.50
79,265.70
73,374.00
79,260.00
83,304
Net Income Available to Common
35,606.70
49,131.50
79,265.70
73,374.00
79,260.00
83,304
EPS (Basic)
2.02
2.87
3.59
2.93
2.94
2.34
Basic Shares Outstanding
17,594.90
17,121.00
22,082.30
25,036.50
26,984.20
35,639.70
EPS (Diluted)
2.02
2.87
3.59
2.93
2.94
2.34
Diluted Shares Outstanding
17,594.90
17,121.00
22,082.30
25,036.50
26,984.20
35,639.70
EBITDA
29,382.80
51,565.60
58,567.70
65,857.00
77,357.00
75,932
Other Operating Expense
-
-
-
1,465.00
600.00
598
Non-Operating Interest Income
77.00
221.50
120.90
70.00
117.00
2,729

About uniQure

View Profile
Address
Paasheuvelweg 25a
Amsterdam Noord-Holland 1105 BP
Netherlands
Employees -
Website http://www.uniqure.com
Updated 07/08/2019
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.